{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:57:52Z","timestamp":1793656672525,"version":"4.5.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ejim.2026.106896","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T19:52:17Z","timestamp":1776973937000},"page":"106896","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Efficacy of Aldosterone synthase inhibitors in uncontrolled and resistant hypertension: A systematic review and updated meta-analysis with grade assessment"],"prefix":"10.1016","volume":"150","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3580-0783","authenticated-orcid":false,"given":"Mrunalini","family":"Dandamudi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisha","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6003-4873","authenticated-orcid":false,"given":"Muhammad Sharjeel","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Huzaifa","family":"Khattak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navya","family":"Mandalapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4034-8374","authenticated-orcid":false,"given":"Terezia Toni","family":"Khairallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6482-5920","authenticated-orcid":false,"given":"Larissa Ara\u00fajo","family":"de Lucena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonida","family":"Pjetrushaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2026.106896_bib0001","unstructured":"International society of hypertension global hypertension practice guidelines Hypertension [Internet] 2020 . [cited 2026 Jan 19]. Available from: https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.120.15026."},{"issue":"12","key":"10.1016\/j.ejim.2026.106896_bib0002","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"issue":"18","key":"10.1016\/j.ejim.2026.106896_bib0003","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jacc.2025.05.007","article-title":"2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults","volume":"86","author":"Jones","year":"2025","journal-title":"JACC"},{"key":"10.1016\/j.ejim.2026.106896_bib0004","article-title":"The unrecognized prevalence of primary aldosteronism","author":"M Brown","year":"2020","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.ejim.2026.106896_bib0005","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diab Endocrinol"},{"issue":"38","key":"10.1016\/j.ejim.2026.106896_bib0006","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1093\/eurheartj\/ehac352","article-title":"Aldosterone in chronic kidney disease and renal outcomes","volume":"43","author":"Verma","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2026.106896_bib0007","unstructured":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice guidelines. Hypertension [Internet]. [cited 2026 Jan 19]. Available from: https:\/\/www.ahajournals.org\/doi\/10.1161\/hyp.0000000000000065."},{"issue":"10008","key":"10.1016\/j.ejim.2026.106896_bib0008","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejim.2026.106896_bib0009","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.ejim.2026.106896_bib0010","doi-asserted-by":"crossref","first-page":"e557","DOI":"10.1210\/clinem\/dgae823","article-title":"Aldosterone synthase inhibitors: a revival for treatment of renal and cardiovascular diseases","volume":"110","author":"Azizi","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ejim.2026.106896_bib0011","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of Baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2026.106896_bib0012","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2026.106896_bib0013","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2026.106896_bib0014","unstructured":"Cochrane handbook for systematic reviews of interventions Cochrane [Internet]. [cited 2026 Jan 21]. Available from: https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook."},{"key":"10.1016\/j.ejim.2026.106896_bib0015","unstructured":"Lissa1 C. V. 7.1 Heterogeneity statistics | doing meta-analysis in R and exploring heterogeneity using metaforest [Internet]. [cited 2026 Jan 21]. Available from: https:\/\/cjvanlissa.github.io\/Doing-Meta-Analysis-in-R\/heterogeneity-statistics.html."},{"issue":"11","key":"10.1016\/j.ejim.2026.106896_bib0016","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"12","key":"10.1016\/j.ejim.2026.106896_bib0017","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/jama.2023.16029","article-title":"Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the target-HTN randomized clinical trial","volume":"330","author":"Laffin","year":"2023","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ejim.2026.106896_bib0018","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1681\/ASN.0000000849","article-title":"Efficacy and safety of Baxdrostat in participants with CKD and uncontrolled hypertension: a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Dwyer","year":"2026","journal-title":"J Am Soc Nephrol"},{"issue":"14","key":"10.1016\/j.ejim.2026.106896_bib0019","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","article-title":"Efficacy and safety of Baxdrostat in uncontrolled and resistant hypertension","volume":"393","author":"Flack","year":"2025","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ejim.2026.106896_bib0020","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2501440","article-title":"Lorundrostat efficacy and safety in patients with uncontrolled hypertension","volume":"392","author":"Laffin","year":"2025","journal-title":"N Engl J Med"},{"issue":"10532","key":"10.1016\/j.ejim.2026.106896_bib0021","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S0140-6736(25)02549-8","article-title":"Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"407","author":"Azizi","year":"2026","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ejim.2026.106896_bib0022","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/jch.12051","article-title":"Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension","volume":"15","author":"Karns","year":"2013","journal-title":"J Clinic Hypert"},{"issue":"5","key":"10.1016\/j.ejim.2026.106896_bib0023","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of Baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejim.2026.106896_bib0024","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/jama.2025.9413","article-title":"Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension: the launch-HTN randomized clinical trial","volume":"334","author":"Saxena","year":"2025","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.ejim.2026.106896_bib0025","article-title":"Renal denervation for resistant hypertension","volume":"2021","author":"Pisano","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.ejim.2026.106896_bib0026","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s11886-023-01966-8","article-title":"New potential treatments for resistant hypertension","volume":"25","author":"Janakiraman","year":"2023","journal-title":"Curr Cardiol Rep"},{"issue":"11","key":"10.1016\/j.ejim.2026.106896_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2023.101918","article-title":"Baxdrostat: a novel aldosterone synthase inhibitor for treatment resistant hypertension","volume":"48","author":"Dogra","year":"2023","journal-title":"Curr Probl Cardiol"},{"issue":"3","key":"10.1016\/j.ejim.2026.106896_bib0028","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/bph.16247","article-title":"Taming resistant hypertension: the promise of novel pharmacologic approaches and renal denervation","volume":"181","author":"Azzam","year":"2024","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.ejim.2026.106896_bib0029","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/cvr\/cvad165","article-title":"Efficacy of pharmacological and interventional treatment for resistant hypertension: a network meta-analysis","volume":"120","author":"Tian","year":"2024","journal-title":"Cardiovasc Res"},{"issue":"5","key":"10.1016\/j.ejim.2026.106896_bib0030","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11906-023-01282-0","article-title":"Resistant hypertension: disease burden and emerging treatment options","volume":"26","author":"Flack","year":"2024","journal-title":"Curr Hypertens Rep"},{"issue":"12","key":"10.1016\/j.ejim.2026.106896_bib0031","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/jama.2023.16029","article-title":"Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the target-HTN randomized clinical trial","volume":"330","author":"Laffin","year":"2023","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ejim.2026.106896_bib0032","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40256-023-00572-x","article-title":"Results from a randomized, open-label, crossover study evaluating the effect of the aldosterone synthase inhibitor Baxdrostat on the pharmacokinetics of Metformin in healthy Human subjects","volume":"23","author":"Freeman","year":"2023","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.ejim.2026.106896_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1097968","article-title":"The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension","volume":"13","author":"Forzano","year":"2022","journal-title":"Front Endocrinol"},{"issue":"3","key":"10.1016\/j.ejim.2026.106896_bib0034","doi-asserted-by":"crossref","first-page":"H670","DOI":"10.1152\/ajpheart.00419.2023","article-title":"Aldosterone and aldosterone synthase inhibitors in cardiorenal disease","volume":"326","author":"Verma","year":"2024","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2","key":"10.1016\/j.ejim.2026.106896_bib0035","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/CRD.0000000000000665","article-title":"Emerging therapies for treatment-resistant hypertension: A review of lorundrostat and related selective aldosterone synthase inhibitors","volume":"34","author":"Feldman","year":"2026","journal-title":"Cardiol Rev."},{"issue":"1","key":"10.1016\/j.ejim.2026.106896_bib0036","doi-asserted-by":"crossref","first-page":"8","DOI":"10.33696\/Pharmacol.6.048","article-title":"Aldosterone synthase inhibitors for treatment of hypertension and chronic kidney disease","volume":"6","author":"Mikhail","year":"2024","journal-title":"Arch Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.ejim.2026.106896_bib0037","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/MNH.0000000000000878","article-title":"Adverse effects during treatment with renin-angiotensin-aldosterone system inhibitors; should we stay or should we stop?","volume":"32","author":"Leon","year":"2023","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"9","key":"10.1016\/j.ejim.2026.106896_bib0038","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1161\/HYPERTENSIONAHA.123.21494","article-title":"Characteristics of adults with apparent treatment resistant hypertension: six factors impacting prevalence-editorial commentary","volume":"80","author":"Egan","year":"2023","journal-title":"Hypertension"},{"issue":"8","key":"10.1016\/j.ejim.2026.106896_bib0039","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/jhh.2013.140","article-title":"Apparent and true resistant hypertension: definition, prevalence and outcomes","volume":"28","author":"Judd","year":"2014","journal-title":"J Hum Hypertens"},{"issue":"1","key":"10.1016\/j.ejim.2026.106896_bib0040","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvac167","article-title":"Association between aldosterone and hypertension among patients with overt and subclinical hypercortisolism","volume":"7","author":"Inoue","year":"2022","journal-title":"J Endocr Soc"},{"issue":"1","key":"10.1016\/j.ejim.2026.106896_bib0041","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa033263","article-title":"Serum aldosterone and the incidence of hypertension in nonhypertensive persons","volume":"351","author":"Vasan","year":"2004","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejim.2026.106896_bib0042","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2025-003535","article-title":"Comparative efficacy and safety of aldosterone synthase inhibitors in hypertension: a Bayesian network meta-analysis of randomised controlled rials","volume":"12","author":"Dewi","year":"2025","journal-title":"Open Heart"},{"issue":"10","key":"10.1016\/j.ejim.2026.106896_bib0043","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1161\/HYPERTENSIONAHA.122.19280","article-title":"Comparative safety and effectiveness of aldosterone antagonists versus beta-blockers as fourth agents in patients with apparent resistant hypertension","volume":"79","author":"Desai","year":"2022","journal-title":"Hypertension"},{"issue":"Suppl 1","key":"10.1016\/j.ejim.2026.106896_bib0044","first-page":"2586","article-title":"Representativeness of antihypertensive trials: analysis of serious adverse events","volume":"20","author":"Hanlon","year":"2022","journal-title":"Ann Fam Med"},{"issue":"4","key":"10.1016\/j.ejim.2026.106896_bib0045","doi-asserted-by":"crossref","DOI":"10.1161\/HYPERTENSIONAHA.124.23962","article-title":"Efficacy and safety of aldosterone synthase inhibitors for hypertension: a meta-analysis of randomized controlled trials and systematic review","volume":"82","author":"Marzano","year":"2025","journal-title":"Hypertension"},{"issue":"12","key":"10.1016\/j.ejim.2026.106896_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2024.102875","article-title":"Efficacy and safety of aldosterone synthase inhibitors in hypertension: a systematic review and meta- analysis","volume":"49","author":"Siddiqui","year":"2024","journal-title":"Curr Probl Cardiol"},{"issue":"8","key":"10.1016\/j.ejim.2026.106896_bib0047","doi-asserted-by":"crossref","DOI":"10.31083\/RCM39555","article-title":"Efficacy and safety of aldosterone synthase inhibitors for resistant hypertension: a systematic review and meta-analysis","volume":"26","author":"Zhang","year":"2025","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.ejim.2026.106896_bib0048","doi-asserted-by":"crossref","DOI":"10.1177\/14703203251411193","article-title":"Efficacy and safety outcomes of aldosterone synthase inhibitors for resistant hypertension: a meta-analysis of randomized controlled trials","volume":"27","author":"Tu","year":"2026","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"2","key":"10.1016\/j.ejim.2026.106896_bib0049","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2025-003535","article-title":"Comparative efficacy and safety of aldosterone synthase inhibitors in hypertension: a Bayesian network meta-analysis of randomised controlled rials","volume":"12","author":"Dewi","year":"2025","journal-title":"Open Heart"},{"key":"10.1016\/j.ejim.2026.106896_bib0050","article-title":"Efficacy and safety of lorundrostat in uncontrolled hypertension: a meta-analysis","author":"Abouelmagd","year":"2025","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"10.1016\/j.ejim.2026.106896_bib0051","article-title":"Efficacy and safety of lorundrostat in uncontrolled hypertension: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials","author":"Alam","year":"2025","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.ejim.2026.106896_bib0052","article-title":"Lorundrostat for patients with uncontrolled hypertension: a systematic review with meta-analysis and trial sequential analysis","author":"Ribeiro","year":"2025","journal-title":"Am J Hypertens"},{"issue":"6","key":"10.1016\/j.ejim.2026.106896_bib0053","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s40292-025-00742-9","article-title":"Efficacy and safety of lorundrostat in uncontrolled and\/or treatment resistant hypertension: a systematic review and meta-analysis of randomized controlled trials","volume":"32","author":"Mubeen","year":"2025","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"3","key":"10.1016\/j.ejim.2026.106896_bib0054","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.cardfail.2025.05.002","article-title":"Mineralocorticoid receptor antagonists and aldosterone synthase inhibitors: agent comparison with implications for clinical practice and trial design","volume":"32","author":"Ferreira","year":"2026","journal-title":"J Card Fail"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526002013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526002013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T01:15:14Z","timestamp":1785719714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620526002013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":54,"alternative-id":["S0953620526002013"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2026.106896","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Aldosterone synthase inhibitors in uncontrolled and resistant hypertension: A systematic review and updated meta-analysis with grade assessment","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2026.106896","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}],"article-number":"106896"}}